HomeBUSINESS
BUSINESS

Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
(Feb.14.2018)

Takeda Pharmaceutical said on February 13 that it has filed an application in Japan, seeking an additional indication for Adcetris (brentuximab vedotin) as a first-line treatment of CD30-positive Hodgkin’s lymphoma ...
(LOG IN FOR FULL STORY)